Quarterly Statement Of Cash Flows

Daito Pharmaceutical Co., Ltd. - Filing #7289262

Concept As at
2024-11-30
2024-06-01 to
2024-11-30
As at
2024-05-31
As at
2023-11-30
2023-06-01 to
2023-11-30
As at
2023-05-31
Quarterly statement of cash flows
Statement of cash flows
Cash flows from operating activities
Subtotal
2,353,000,000 JPY
2,398,000,000 JPY
Interest and dividends received
38,000,000 JPY
37,000,000 JPY
Interest paid
-54,000,000 JPY
-9,000,000 JPY
Income taxes paid
-515,000,000 JPY
-518,000,000 JPY
Net cash provided by (used in) operating activities
1,840,000,000 JPY
1,946,000,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-4,888,000,000 JPY
-3,627,000,000 JPY
Purchase of investment securities
-6,000,000 JPY
JPY
Proceeds from sale of investment securities
444,000,000 JPY
7,000,000 JPY
Other, net
2,000,000 JPY
14,000,000 JPY
Net cash provided by (used in) investing activities
-5,287,000,000 JPY
-3,616,000,000 JPY
Cash flows from financing activities
Proceeds from long-term borrowings
6,000,000,000 JPY
4,000,000,000 JPY
Repayments of long-term borrowings
-1,449,000,000 JPY
-949,000,000 JPY
Purchase of treasury shares
0 JPY
-2,000,000 JPY
Dividends paid
-464,000,000 JPY
-431,000,000 JPY
Net cash provided by (used in) financing activities
3,964,000,000 JPY
2,609,000,000 JPY
Effect of exchange rate change on cash and cash equivalents
-3,000,000 JPY
38,000,000 JPY
Net increase (decrease) in cash and cash equivalents
514,000,000 JPY
978,000,000 JPY
Cash and cash equivalents
3,241,000,000 JPY
2,727,000,000 JPY
4,585,000,000 JPY
3,607,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.